Cynthia Coan

Currently Shapely serves adults age 18 and older in the states of California, Florida, New York, and Texas. We will soon be expanding to all 50 US states!

We navigate insurance on your behalf and are able to work with the vast majority of insurances to get cost-effective access to GLP-1 medications like Wegovy® and Zepbound® . For patients with commercial insurance, medication co-pays are typically $25 per month but depending on the plan may be higher. At this time, Medicare only covers these medications for patients with diabetes, cardiovascular disease (such as stroke or heart attack), and obstructive sleep apnea.

For members choosing to use insurance for their visits with Shapely, insurance covers any visits with our expert team of providers and dietitians, though you may be responsible for any cost-sharing, such as co-pays, deductibles, and co-insurances. In addition, you will still have a membership fee which covers use of our app, chat features with your Shapely team, access to exclusive education, tracking tools, and concierge support locating medications at local pharmacies.

If you don’t have insurance, or if your insurance doesn’t cover your medication, there are still options.
‍
Shapely can help patients access self-pay programs for FDA-approved medications, such as Wegovy® through NovoCare® and Zepbound® through Lilly Direct®, which may offer discounted pricing for eligible patients.

In some cases, your provider may determine that a compounded medication is clinically appropriate based on your individual needs. When prescribed, compounded medications are offered on a self-pay basis, with pricing starting at $99 per month for compounded semaglutide and $166 per month for compounded tirzepatide.

‍Shapely is not affiliated with Novo Nordisk, Eli Lilly, or their patient programs. Compounded medications are not FDA-approved and are prepared by state-licensed pharmacies based on a provider’s clinical judgment.

Patients on FDA-approved GLP-1 medications like Ozempic and Wegovy lose an average 15% of their weight when combined with diet and exercise. With Mounjaro and Zepbound, average weight loss is 20.9%. Note that results are not guaranteed and may vary. With other medications, weight loss can be up to 10%. Ultimately, your weight loss journey is a personal one, and your Shapely team will be by your side to help you achieve your best results

Typically, we find that patients taking FDA-approved GLP-1 agonists such as Ozempic and Wegovy will lose 10% of weight by 6 months and 15% within 1 year. Results will vary by patient, intervention, and medication prescribed (if appropriate). We find that patients benefit from at least a 12 month comprehensive weight-loss program to establish the proper habits to sustain long-term weight loss

If you are not a good candidate for GLP-1 agonists, our providers will offer different modalities of weight loss for you, including alternative medications, lifestyle modification, continuous glucose monitoring, and other tools.

Recent labs are strongly recommended (but not required) prior to initiation of most weight loss medications. We will either order labs for you or accept labs completed within 6 months prior to program enrollment. Labs are  typically covered by insurance though there may be a co-pay. For patients without insurance, we offer labs for a flat-rate of $75, requiring you to go to a Labcorp location for lab draw.